

Amendments to the Specification:

Please amend the second paragraph at page 4 as follows:

In general, the polypharmacophoric scaffolds comprise a scaffold unit having at least two pharmacophoric units appended thereto, whereby each is capable of interacting at a biological site and/or eliciting or inhibiting a desired biological response. In certain preferred embodiments, the pharmacophoric units are selected for their ability to elicit a response at two or more biological receptor sites that preferably act in concert and optionally are either physically or spatially close (e.g., DA agonist and DAT receptors) or can be functionally connected (for example, via the ~~polypharmacophoreic~~ polypharmacophoric unit). In certain embodiments, the scaffold units and/or the pharmacophoric units have one or more modifier units attached thereto, whereby these modifier units are ~~selected~~ selected to facilitate the delivery, synthesis, activation, absorption, solubility or detection (e.g., by the use of fluorescent or radioactive moieties, or biotin, to name a few) of the scaffold pharmacophoric units.